Deutsche Bank Starts Neurocrine Bio. (NBIX) at Buy; Upside in 2012 as Investors Gain Confidence in Pipeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. GNK
7. HTFL
8. ADYEN:NA
9. DVLT
10. ADYYF

March 15, 2012 4:41 PM EDT
Get Alerts NBIX Hot Sheet
Price: $152.72 +1.26%

Rating Summary:
    30 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Deutsche Bank initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy. PT $15.00.

Deutsche analyst said, "We rate NBIX shares BUY because currently shares reflect only value to Elagolix in endometriosis & zero to pipeline. We believe upside this year will be driven by increased investor confidence in VMAT2 and Elagolix in uterine fibroids. Our report focuses on why we think both have a high degree of success in phase 2 & phase 3."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $8.16 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Deutsche Bank